← Back
$RYTM All transactions

RHYTHM PHARMACEUTICALS, INC.

M 10b5-1 Plan

$ Value

$0

Shares

7,031

Price

$0

Filed

Jun 10

Insider

Name

Cramer Pamela J.

Title

Chief Human Resources Officer

CIK

0001873517

Roles

Officer

Transaction Details

Transaction Date

2025-06-06

Code

M

Table

Derivative

Ownership

Direct

Equity Swap

No

Shares After

28,128

Footnotes

The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 16, 2024. | The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $68.00 to $68.18 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. | The stock options were granted on February 9, 2022. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.

Filing Info

Accession No.

0001104659-25-058188

Form Type

4

Issuer CIK

0001649904

Cramer Pamela J.'s History

Date Ticker Type Value
2026-02-01 RYTM M
2026-02-01 RYTM F $516K
2026-02-01 RYTM M $0
2026-02-01 RYTM M $0
2026-02-01 RYTM M $0
2026-02-01 RYTM M $0
2025-12-11 RYTM M $92K
2025-12-11 RYTM $372K
2025-12-11 RYTM M $0
2025-11-20 RYTM M $92K

Other Insiders at RYTM (90d)

Insider Bought Sold Last
German Christopher Paul
Corporate Controller & CAO
2026-02-01
Popovits Kimberly J 2026-04-01
Meeker David P
President and CEO
2026-02-01
Smith Hunter C
Chief Financial Officer
$703K 2026-02-05
Mazabraud Yann
EVP, Head of International
2026-04-01
Lee Jennifer Kayden
EVP, Head of North America
2026-02-01
Cramer Pamela J.
Chief Human Resources Officer
2026-02-01
Shulman Joseph
Chief Technical Officer
2026-02-01
Garfield Alastair
Chief Scientific Officer
2026-02-01